Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

NIAID halts Lilly COVID-19 antibody study

By Brian Buntz | October 27, 2020

An arm of NIH has ended a clinical trial investigating the use of Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab) to treat hospitalized COVID-19 patients.

In separate news, HHS plans to allocate 300,000 doses of the monoclonal antibody immediately, according to an announcement.

While the drug shows promise in treating mild-to-moderate COVID-19 infections, the ACTIV-3 trial involving severe cases of the disease showed little benefit, according to the National Institute of Allergy and Infectious Diseases (NIAID).

The study, which involved 326 participants, involved hospitalized patients treated with 7000 mg of bamlanivimab. In a statement, Lilly acknowledged that “hospitalized patients may have less benefit from neutralizing antibodies” than those with less-severe COVID-19 infections.

Results from BLAZE-1, an ongoing Phase 2 trial for patients recently diagnosed with COVID-19 in an outpatient setting, have been more encouraging. Patients in that trial exhibited reduced viral load and symptoms, according to the company. In a statement, the company said it is “confident” based on preliminary data that bamlanivimab monotherapy “may prevent progression of disease for those earlier in the course of COVID-19.”

BLAZE-1 combined bamlanivimab with the antiviral remdesivir, which FDA recently approved as a COVID-19 treatment.

Lilly has filed for FDA emergency use authorization to use bamlanivimab and Olumiant, a rheumatoid arthritis therapy, to treat patients with SARS-CoV-2 infections.

This story was originally published on Oct. 27, and updated on Nov. 10. 


Filed Under: clinical trials, Drug Discovery
Tagged With: bamlanivimab, coronavirus, covid-19, Eli Lilly & Co., LY-CoV555
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE